Cure8 research brief
People with ulcerative colitis and their clinicians are interested in biomarkers that might predict who will respond to vedolizumab, an anti-integrin biologic. This study explored mucosal gene-expression signals but did not find a reproducible predictor, highlighting that no reliable pre-treatment test emerged here.
Researchers studying IBD biomarkers or vedolizumab response; clinicians who follow biomarker research; patients considering or receiving vedolizumab who are curious about predictive tests.
This study reports an exploratory biomarker analysis rather than a validated predictive test. The four-gene panel was identified by repeated LASSO selection but showed poor and inconsistent performance when tested in independent samples, and selection appeared unstable on bootstrap analysis.
The interferon-γ–related panel showed a non-significant directional difference between responders and non-responders. The authors caution that results reflect post-selection separation in the discovery set and do not establish reproducible predictive performance, tissue specificity, or a definitive signature.
Study used reconstructed public cohorts and independent validation sets but had small sample sizes and differing endpoints/scales across cohorts. The authors present these findings as exploratory (abstract-level summary) and do not claim a validated predictive biomarker. this is an academic study; the panel requires larger, prospectively designed validation before clinical use.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
